Online citations, reference lists, and bibliographies.
← Back to Search

Management Of Malignant Pleural Mesothelioma: A French Multicenter Retrospective Study (GFPC 0802 Study)

C. Raynaud, L. Greillier, J. Mazières, I. Monnet, B. Mastroianni, G. Robinet, G. Fraboulet, A. Dixmier, H. Bérard, R. Lamy, J. Letreut, H. Lena, G. Oliviero, S. Botta, A. Vergnenègre, I. Borget, C. Chouaid
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundMalignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients’ profiles and management in daily practice in France.MethodsObservational retrospective study. Data were collected from medical files. All patients with histologically proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites.ResultsFour hundred and six patients were included in 37 sites: mean age 68.9 ± 9.8 years, male predominance (sex ratio 3.27), latency of the disease 45.7 years, epithelioïd type 83 %. Diagnosis was made using thoracoscopy in 80.8 % of patients. Radical surgery was performed in 6.2 % of cases. Chemotherapy was administered to 74.6 % of patients. First line regimens consisted mainly of platinum + pemetrexed (91 %) or pemetrexed alone (7 %). Objective response rate was 17.2 % and another 41.6 % of patients experienced disease stabilization. Half of these patients underwent second line chemotherapy (platinium + pemetrexed 31.6 %, pemetrexed alone 24.6 %), resulting in a 6 % response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4 % of cases.ConclusionsThe management of MPM in France is usually in accordance with guidelines. Response rates are somewhat lower than those described in clinical trials.
This paper references
10.12659/MSM.890020
Malignant pleural mesothelioma: A single-center experience in Turkey
A. Sezer (2014)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1002/14651858.CD003880.PUB4
Radiotherapy for malignant pleural mesothelioma.
E. Chapman (2006)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1007/s10147-013-0619-5
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy
G. Toyokawa (2013)
The French mesothelioma network
F Galateau-Salle (1998)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
Société de Pneumologie de Langue Française . Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural
NJ Vogelzang (2006)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1183/09031936.00005111
Temporal patterns of occupational asbestos exposure and risk of pleural mesothelioma
A. Lacourt (2011)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial
G Zalcman
10.1200/JCO.2014.32.15_SUPPL.7532
Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).
R. Hassan (2014)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1093/ANNONC/MDJ962
Pemetrexed and malignant pleural mesothelioma.
M. Marangolo (2006)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
The French mesothelioma network from
F Galateau-Salle (1998)
10.1136/thoraxjnl-2013-204161
Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis
A. Reid (2014)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1200/JCO.2015.33.15_SUPPL.7500
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
G. Zalcman (2015)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1684/bdc.2013.1857
[Malignant pleural mesothelioma: 2013 state of the art].
K. Campbell (2013)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1016/J.ANNPAT.2014.01.009
Mésothéliome : les dispositifs en place en France « le réseau mésothéliome » 1998–2013
F. Galateau-Sallé (2014)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/j.annpat.2014.01.009
[The French mesothelioma network from 1998 to 2013].
F. Galateau-Sallé (2014)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.7314/APJCP.2012.13.11.5735
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years' experience in Turkey.
S. Berk (2012)
10.1016/S0761-8425(06)71779-X
La conférence d'experts de la Société de Pneumologie de Langue Française (SPLF) sur le mésothéliome pleural malin (MPM) : des recommandations utiles et nécessaires
A. Scherpereel (2006)
10.1200/JCO.2014.32.15_SUPPL.7507
Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma.
P. Szlosarek (2014)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.3978/j.issn.2072-1439.2013.08.08
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
10.1016/s0761-8425(06)71780-6
Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural Conférence d'experts - texte long
Pr P. Godard (2006)
10.1684/BDC.2013.1857
Mésothéliomes malins pleuraux : le point en 2013
Karine Campbell (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar